GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota

BEVERLY HILLS, Calif.: Deepening relationship between GT Biopharma and Dr. Jeffrey Miller TriKE™ improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model GTB-3550 continues to demonstrate clinical success without significant toxicities BEVERLY HILLS, Calif., July 7, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage...

Click to view original post